Dae Hwa Pharm Co (XKRX:067080) Debt-to-Equity : 1.55 (As of Sep. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Dae Hwa Pharm Co Debt-to-Equity?

Dae Hwa Pharm Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩102,534 Mil. Dae Hwa Pharm Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩5,363 Mil. Dae Hwa Pharm Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was ₩69,683 Mil. Dae Hwa Pharm Co's debt to equity for the quarter that ended in Sep. 2024 was 1.55.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dae Hwa Pharm Co's Debt-to-Equity or its related term are showing as below:

XKRX:067080' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.52 Med: 0.77 Max: 1.6
Current: 1.55

During the past 13 years, the highest Debt-to-Equity Ratio of Dae Hwa Pharm Co was 1.60. The lowest was 0.52. And the median was 0.77.

XKRX:067080's Debt-to-Equity is ranked worse than
92.98% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs XKRX:067080: 1.55

Dae Hwa Pharm Co Debt-to-Equity Historical Data

The historical data trend for Dae Hwa Pharm Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dae Hwa Pharm Co Debt-to-Equity Chart

Dae Hwa Pharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.65

0.78

0.88

1.16

1.51

Dae Hwa Pharm Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															1.49	1.51	1.60	1.54	1.55

Competitive Comparison of Dae Hwa Pharm Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Dae Hwa Pharm Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dae Hwa Pharm Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dae Hwa Pharm Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dae Hwa Pharm Co's Debt-to-Equity falls into.

Dae Hwa Pharm Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dae Hwa Pharm Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(102795.326	+	7729.55)	/	73231.783
	=	1.51

Dae Hwa Pharm Co's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(102534.462	+	5362.894)	/	69683.299
	=	1.55

Dae Hwa Pharm Co (XKRX:067080) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dae Hwa Pharm Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dae Hwa Pharm Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dae Hwa Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dae Hwa Pharm Co Ltd (XKRX:067080) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

495 Hanu-ro, Hoengseong-eup, Hoengseong-gun, Seoul, Gangwon-do, KOR, 225-804

Website

http://www.dhpharm.co.kr

Dae Hwa Pharm Co Ltd is a specialized pharmaceutical company. It is mainly involved in manufacturing and distribution of pharmaceutical products. The company controls approximately 70% of the domestic transdermal drug delivery system market. The company offers analgesics and anti-inflammatory drugs, antihistamines, skeletal muscle relaxants, and cardiovascular drugs. Its products are exported to Asia, South America, Africa, and the Middle East.

Dae Hwa Pharm Co Headlines

No Headlines